Myriad Genetics reported higher-than-expected Q3 2026 revenue driven by a 7% sequential increase in average revenue per test. The company also raised its full-year 2026 revenue expectations and agreed to sell its Prenatal Health business to Labcorp.
Myriad Genetics reported higher-than-expected Q3 2026 revenue driven by a 7% sequential increase in average revenue per test. The company also raised its full-year 2026 revenue expectations and agreed to sell its Prenatal Health business to Labcorp.